SCHEMBL15058849

SCHEMBL15058849

O=C(OCC1c2ccccc2-c2ccccc21)OC(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
FABP5 Q01469 3/20 0.54
FABP7 O15540 2/20 0.54
EPHX2 P34913 1/20 0.51
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
HTR2A P28223 1/20 0.44
CASP3 P42574 2/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL44676 0.92 KMT2A (0.58) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL30752070 0.92 KMT2A (0.49) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL29598813 0.91 FABP5 (0.54) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL7767154 0.91 FABP5 (0.54) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL393445 0.90 KMT2A (0.50) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL30396315 0.90 KMT2A (0.50) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL8612414 0.90 KMT2A (0.54) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL7720044 0.87 KMT2A (0.58) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL34469817 0.87 FABP5 (0.50) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL30807400 0.87 KMT2A (0.45) KMT2AFABP5FABP7EPHX2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106716237-B Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element 日产化学工业株式会社 2020-09-25 CN disclosed
EP-2797879-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN AND NEUROPATHIC PAIN BIO PHARM SOLUTIONS CO LTD (KR) 2018-12-26 EP disclosed
US-9872847-B2 Phenyl carbamate compounds for use in preventing or treating a movement disorder BIO-PHARM SOLUTIONS CO., LTD. (KR) 2018-01-23 US disclosed
EP-2797878-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING STROKE BIO-PHARM SOLUTIONS CO LTD (KR) 2017-08-16 EP disclosed
EP-2797880-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY BIO-PHARM SOLUTIONS CO LTD (KR) 2017-03-01 EP disclosed
US-20160024000-A1 Phenyl Carbamate Compounds for Use in Preventing or Treating a Movement Disorder BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
EP-2968212-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME Bio-Pharm Solutions Co., Ltd. (KR) 2016-01-20 EP disclosed
EP-2968210-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY AND EPILESY-RELATED SYNDROMES Bio-Pharm Solutions Co., Ltd. (KR) 2016-01-20 EP disclosed
EP-2968213-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING A MOVEMENT DISORDER Bio-Pharm Solutions Co., Ltd. (KR) 2016-01-20 EP disclosed
EP-2797879-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN AND NEUROPATHIC PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2014-11-05 EP disclosed
WO-2014142520-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 WO disclosed
WO-2014142477-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY AND EPILESY-RELATED SYNDROMES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 WO disclosed
WO-2014142518-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING A MOVEMENT DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 WO disclosed
US-20140275243-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY AND EPILESY-RELATED SYNDROMES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 US disclosed
WO-2013100568-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING STROKE BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-07-04 WO disclosed
WO-2013100569-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING MULTIPLE SCLEROSIS BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-07-04 WO disclosed
WO-2013100570-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILESY BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-07-04 WO disclosed
WO-2013100567-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN AND NEUROPATHIC PAIN BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-07-04 WO disclosed
US-20130165408-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILESY BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed
US-20130165409-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165408-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILESY CHAT, BCHE, GABBR1 KMT2A 549/4885FABP5 2273/4885FABP7 369/4885
US-20130165409-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN ACHE, HDAC3, TRPV1 KMT2A 687/4885FABP5 1581/4885FABP7 1121/4885
US-20140275243-A1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY AND EPILESY-RELATED SYNDROMES CACNA1A, KDM1A, KDM3A KMT2A 171/4885FABP5 1599/4885FABP7 719/4885
US-20160024000-A1 Phenyl Carbamate Compounds for Use in Preventing or Treating a Movement Disorder COMT, CHAT, ACHE KMT2A 404/4885FABP5 1180/4885FABP7 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.